LON:INDV Indivior (INDV) Share Price, News & Analysis GBX 1,238 +19.00 (+1.56%) As of 07/24/2025 Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesBuy This Stock About Indivior Stock (LON:INDV) Get Indivior alerts:Sign Up Key Stats Today's Range 1,230▼ 1,26450-Day Range 1,238▼ 1,23852-Week Range 548.71▼ 1,264Volume8.46 million shsAverage Volume798,658 shsMarket Capitalization£1.93 billionP/E RatioN/ADividend Yield4.48%Price TargetN/AConsensus RatingN/A Company Overview Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia. Read More Receive INDV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INDV Stock News HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)June 5, 2026 | theglobeandmail.comIndivior (LON:INDV) Stock Crosses Below 200-Day Moving Average - Here's WhyJune 3, 2026 | americanbankingnews.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free. | Behind the Markets (Ad)Indivior Pharmaceuticals Inc. (INDV) is a great choice for 'trend' investors, here's whyMay 18, 2026 | msn.comIndivior Pharmaceuticals Inc Ordinary Share INDVMay 13, 2026 | morningstar.comMIndivior Earnings Call Highlights SUBLOCADE-Fueled MomentumMay 3, 2026 | theglobeandmail.comIs It Too Late To Consider Indivior Pharmaceuticals (INDV) After A 214% One-Year Surge?May 3, 2026 | finance.yahoo.comHere's why momentum in Indivior Pharmaceuticals Inc. (INDV) should keep goingMay 1, 2026 | msn.comSee More Headlines INDV Stock Analysis - Frequently Asked Questions How have INDV shares performed this year? Indivior's stock was trading at GBX 1,238 at the beginning of 2026. Since then, INDV stock has increased by 0.0% and is now trading at GBX 1,238. How do I buy shares of Indivior? Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some other companies that Indivior investors own include Futura Medical (FUM), Bigblu Broadband (BBB), Directa Plus (DCTA), Lakehouse (LAKE), Kingfisher (KGF), Sirius XM (SIRI) and Aquila Services Group (AQSG). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolLON:INDV CIKN/A Webindivior.com Phone+44-1753-217800FaxN/AEmployees1,000Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.21) Trailing P/E RatioN/A Forward P/E Ratio1,167.92 P/E Growth-5.57Net Income-£2.36 million Net Margins14.30% Pretax MarginN/A Return on Equity-41.70% Return on Assets2.37% Debt Debt-to-Equity Ratio-141.86 Current Ratio0.90 Quick Ratio1.52 Sales & Book Value Annual Sales£1.40 billion Price / Sales1.38 Cash FlowGBX 461.92 per share Price / Cash Flow2.68 Book ValueGBX (126.42) per share Price / Book-9.79Miscellaneous Outstanding Shares156,209,528Free FloatN/AMarket Cap£1.93 billion OptionableNot Optionable Beta0.19 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:INDV) was last updated on 6/9/2026 by MarketBeat.com Staff. From Our PartnersJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Indivior With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
